title: [Growth hormone treatment of familial hypophosphatemic rickets].
abstract: X-linked hypophosphatemic rickets (XLHR) is frequently associated with growth retardation and short adult stature, even with an appropriate conventional treatment associating phosphate and calcitriol or 1 alpha-hydroxyvitamin D. Its pathogenesis is unclear; growth hormone (GH) secretion is usually normal. Six children with XLHR and growth retardation were treated with GH during 6 years. In addition, they received the conventional treatment. At the beginning of the treatment mean age was 7.8 +/- 1.8 years, and height mean Z score was -3.4 +/- 0.5. A control group was composed of six children with XLHR (age: 7.9 +/- 2.5 years) receiving the conventional treatment only. Under GH treatment statural growth was improved, with significant increase in Z score and predicted adult height; the height gain was significantly higher in the GH treated group as compared with the group receiving the conventional treatment only. In addition, radial bone mineral density increased significantly under GH treatment. GH treatment thus appears to be a useful treatment to improve statural growth in children with XLHR.
authors.affiliation: Unité d'endocrinologie, université de Pise, Italie.
authors.forename: G
authors.initials: G
authors.lastname: Saggese
authors.forename: G I
authors.initials: GI
authors.lastname: Baroncelli
authors.forename: S
authors.initials: S
authors.lastname: Barsanti
mesh_terms: D000328:Adult; D001827:Body Height / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D002117:Calcitriol / Q000627:therapeutic use; D002648:Child; D002762:Cholecalciferol / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000188:drug therapy* / Q000235:genetics*; D013006:Growth Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007015:Hypophosphatemia, Familial / Q000150:complications* / Q000188:drug therapy; D008297:Male; D010710:Phosphates / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010710:Phosphates; D002762:Cholecalciferol; D013006:Growth Hormone; D002117:Calcitriol
vernacular_title: Traitement par hormone de croissance du rachitisme hypophosphatémique familial.